| Primary |
| Neuroendocrine Tumour |
20.0% |
| Acromegaly |
13.8% |
| Carcinoid Tumour |
11.4% |
| Carcinoid Syndrome |
8.5% |
| Hypertension |
5.1% |
| Short-bowel Syndrome |
4.6% |
| Neuroendocrine Carcinoma |
4.0% |
| Diarrhoea |
3.7% |
| Pain |
3.5% |
| Gastrinoma |
3.1% |
| Gastrointestinal Obstruction |
3.0% |
| Pituitary Tumour Benign |
3.0% |
| Crohn's Disease |
2.2% |
| Hypoglycaemia |
2.2% |
| Pancreatic Neuroendocrine Tumour |
2.2% |
| Carcinoid Tumour Of The Small Bowel |
2.1% |
| Small Intestine Carcinoma |
2.1% |
| Post Gastric Surgery Syndrome |
2.0% |
| Pancreatitis Chronic |
1.8% |
| Metastatic Carcinoid Tumour |
1.7% |
|
| Death |
21.5% |
| Vomiting |
11.2% |
| Diarrhoea |
7.7% |
| Nausea |
5.6% |
| Weight Decreased |
5.6% |
| Malaise |
5.0% |
| Malignant Neoplasm Progression |
4.1% |
| Blood Pressure Increased |
3.8% |
| Surgery |
3.8% |
| Neoplasm Malignant |
3.5% |
| Asthenia |
3.2% |
| Abdominal Pain |
2.9% |
| Fatigue |
2.9% |
| Hypotension |
2.9% |
| Intestinal Obstruction |
2.9% |
| White Blood Cell Count Decreased |
2.9% |
| Pyrexia |
2.7% |
| Renal Failure |
2.7% |
| Injection Site Pain |
2.4% |
| Stress |
2.4% |
|
| Secondary |
| Neuroendocrine Tumour |
18.8% |
| Vipoma |
16.4% |
| Carcinoid Syndrome |
10.9% |
| Carcinoid Tumour |
10.5% |
| Acromegaly |
6.8% |
| Diarrhoea |
5.4% |
| Product Used For Unknown Indication |
4.9% |
| Metastatic Carcinoid Tumour |
4.4% |
| Hypertension |
3.0% |
| Pain |
2.3% |
| Pancreatic Neuroendocrine Tumour |
2.1% |
| Short-bowel Syndrome |
2.1% |
| Thyroid Cancer |
2.1% |
| Small Intestine Carcinoma |
1.8% |
| Crohn's Disease |
1.6% |
| Intestinal Obstruction |
1.5% |
| Neoplasm Malignant |
1.5% |
| Post Gastric Surgery Syndrome |
1.4% |
| Hepatic Neoplasm |
1.3% |
| Pituitary-dependent Cushing's Syndrome |
1.2% |
|
| White Blood Cell Count Increased |
15.1% |
| Weight Decreased |
11.1% |
| Malaise |
8.3% |
| Vomiting |
8.3% |
| Nausea |
6.0% |
| Death |
5.1% |
| Diarrhoea |
4.8% |
| Platelet Count Decreased |
4.8% |
| Pain In Extremity |
4.6% |
| Abdominal Pain |
4.0% |
| Fatigue |
3.4% |
| Incorrect Route Of Drug Administration |
3.1% |
| Oophorectomy |
3.1% |
| Tricuspid Valve Incompetence |
3.1% |
| Tumour Necrosis |
3.1% |
| Decreased Appetite |
2.6% |
| Disseminated Intravascular Coagulation |
2.6% |
| Dizziness |
2.3% |
| Intestinal Obstruction |
2.3% |
| Malignant Neoplasm Progression |
2.3% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.5% |
| Diffuse Large B-cell Lymphoma |
9.4% |
| Drug Use For Unknown Indication |
9.4% |
| Hiv Infection |
5.7% |
| Hypertension |
5.1% |
| Prophylaxis |
4.8% |
| Cancer Pain |
4.6% |
| Diarrhoea |
4.5% |
| Pain |
4.2% |
| Angina Pectoris |
2.6% |
| Mitochondrial Toxicity |
2.6% |
| Ovarian Cancer Recurrent |
2.5% |
| Diabetes Mellitus |
2.4% |
| Pancreatic Neuroendocrine Tumour |
2.3% |
| Acromegaly |
2.3% |
| Nausea |
2.2% |
| Colorectal Cancer |
1.8% |
| Constipation |
1.8% |
| Breast Cancer |
1.7% |
| Hepatic Cirrhosis |
1.7% |
|
| Vomiting |
13.5% |
| Weight Decreased |
11.6% |
| White Blood Cell Count Decreased |
7.2% |
| Respiratory Failure |
6.8% |
| Death |
6.3% |
| Pancreatic Insufficiency |
5.8% |
| Oedema |
4.8% |
| Thrombocytopenia |
4.8% |
| Diarrhoea |
4.3% |
| Sinusitis |
4.3% |
| Neutropenia |
3.4% |
| Pneumonia |
3.4% |
| Pyrexia |
3.4% |
| Stomatitis |
3.4% |
| Wound |
3.4% |
| Dehydration |
2.9% |
| Renal Failure Acute |
2.9% |
| Wound Dehiscence |
2.9% |
| Ileus |
2.4% |
| Nephrolithiasis |
2.4% |
|
| Interacting |
| Atrial Fibrillation |
100.0% |
|
| Malignant Neoplasm Progression |
100.0% |
|
